Boston Scientific study demonstrates real-world benefits of bronchial thermoplasty

Boston Scientific has announced new data from a long-term study demonstrating the effectiveness of bronchial thermoplasty in the treatment of severe asthma.

Findings from a three-year follow-up cohort to its real-world PAS2 study showed that the 190 patients enrolled achieved similar reductions in severe exacerbations, hospitalisations and emergency room visits when compared to the clinical trial AIR2.

Patients involved in these studies received bronchial thermoplasty treatment using Boston Scientific's Alair System, the first non-pharmacologic, device-based treatment for severe, persistent asthma.

This shows that bronchial thermoplasty represents an effective, durable and safe treatment for severe asthmatics with poorer asthma control, and marks the first large-scale, prospective study of this treatment approach performed in a post-market setting.

Art Butcher, senior vice-president and president for endoscopy at Boston Scientific, said: "We will continue to work to make sure that patients have access and coverage for this established, important treatment that has been shown to improve asthma-related quality of life."

Alair is approved in both the US and Europe for the treatment of adult patients with severe asthma that has not been well controlled with medication.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.